We are live on ! Find out more

Sanofi

SNY

Market cap $96.4B

40.25 USD

+0.02

0.05%

At close Updated Oct 9, 10:00 AM EDT

1 day

0.05%

5 days

1.05%

1 month

-6.07%

3 months

-8.31%

6 months

-14.51%

Year to date

-16.55%

1 year

-17.55%

5 years

-17.32%

10 years

4.11%

About: Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Employees: 74,846

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 50%

Neutral 42.9%

Negative 7.1%

Press Release : Availability of the aide-mémoire for Q3 2026 results

Availability of the aide-mémoire for Q3 2026 results Paris, France – October 6, 2026. Sanofi announced today the availability of the aide-mémoire for Q3 2026 results on the "Investors" page of sanofi.com: Third quarter 2026 results Prepared each quarter, this document is intended to support financial modelling of the quarterly results.

Press Release : Availability of the aide-mémoire for Q3 2026 results

24/7 Wall Street

Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up

Sanofi is carrying the Nuvaxovid COVID-19 shot into the fall vaccination season, and buyers are rewarding shares of licensor Novavax (NASDAQ:NVAX) far more heavily than the rest of biotech. Novavax stock has rose 17% during afternoon trading, reaching $12.

Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up

As First Dupixent MDL Hearing Opens, Weitz & Luxenberg Points to Sanofi's Own Words on a Cancer That Hides Behind Eczema

NEW YORK--(BUSINESS WIRE)--Weitz & Luxenberg, which represents more people in the Dupixent litigation than any other firm, appeared this past Friday at the first hearing in the federal multidistrict litigation over allegations that Dupixent (dupilumab) can cause, accelerate or unmask cutaneous T-cell lymphoma (CTCL). Judge Zahid N. Quraishi of the U.S. District Court for the District of New Jersey held the initial case management conference for In re: Dupixent (dupilumab) Products Liability.

As First Dupixent MDL Hearing Opens, Weitz & Luxenberg Points to Sanofi's Own Words on a Cancer That Hides Behind Eczema

Zacks Investment Research

Sanofi, Regeneron Expand Immunology Alliance With New Antibodies

SNY and REGN expand their longstanding alliance to four new antibodies targeting type II inflammation, with billions in potential payments.

Sanofi, Regeneron Expand Immunology Alliance With New Antibodies

Regeneron And Sanofi Announce A Win-Win Collaboration Expansion

Regeneron and Sanofi announced a strategic expansion of their antibody collaboration, targeting IL-4/IL-13 pathways for next-generation inflammation and immunology therapies. The deal grants REGN $1B upfront and up to $7B in milestones, with a 50:50 global profit split for new assets, enhancing alignment and commercial potential. REGN and SNY now have several shots on goal to address Dupixent loss-of-exclusivity and emerging long-acting competitors, with key assets potentially launching from 2030 onward.

Regeneron And Sanofi Announce A Win-Win Collaboration Expansion

Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion

Regeneron Pharmaceuticals NASDAQ: REGN and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases, adding four Regeneron-originated antibody programs and establishing a new equal-sharing economic framework for the assets.

Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion

Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion

Regeneron and Sanofi NASDAQ: SNY announced an expanded collaboration focused on developing next-generation medicines for type 2 inflammatory diseases, extending an alliance that has produced the blockbuster therapy DUPIXENT.

Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion

Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion

The companies will share development and commercialization costs as well as potential future profits from the new drugs, they said.

Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion

Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal

French drugmaker Sanofi said on Thursday it ‌would pay US partner Regeneron $1 billion upfront and up to $7 billion more in milestone payments to add four next-generation, long-acting immunology antibodies to ⁠the partnership behind their blockbuster eczema drug Dupixent.

Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal

Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies

Sanofi and Regeneron expand global Alliance with multiple nex t-generation, long-acting immunology antibodies REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the Alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting pre-clinical antibodies from Regeneron Regeneron to receive $1 billion upfront, with potential for up to an additional $7 billion in future milestone payments; companies to equally share development and commercialization costs, as well as any future profits Sanofi and Regeneron to host a conference call for investors and analysts today at 14:00 CET/8:00am ET Paris and Tarrytown, NY, October 1, 2026. Sanofi and Regeneron Pharmaceuticals, Inc. today announce an expansion of their longstanding antibody collaboration, adding multiple next-generation, long-acting antibodies to the Alliance that has jointly established Dupixent® (dupilumab) as the world-leading treatment for diseases driven by type 2 inflammation.

Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies

See News Rankings

Price charts implemented using Lightweight Charts™